celecoxib has been researched along with Carcinoma, Hepatocellular in 43 studies
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma." | 7.91 | Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. ( Chen, L; Deng, X; Hu, J; Li, X; Qiu, Z; Sheng, L; Zhang, C; Zheng, G; Zhou, J, 2019) |
| "Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed." | 7.79 | Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. ( Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M, 2013) |
| "To evaluate effects of celecoxib (a selective cox-2 inhibitor)combined with fluvastatin (a HMG-CoA reductase inhibitor) on tumor growth and cell apoptosis in hepatocellular carcinoma xenograft in nude mice." | 7.76 | [Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellular carcinoma]. ( Gao, J; Ge, YS; Jia, WD; Li, JS; Ma, JL; Xu, GL; Yu, JH, 2010) |
| " We have reported that apoptosis can be restored in human multidrug-resistant (MDR) hepatocellular carcinoma cell lines by celecoxib." | 7.75 | Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. ( Bottini, C; Fantappiè, O; Mazzanti, R; Platini, F; Solazzo, M; Tessitore, L, 2009) |
| "Celecoxib can inhibit the proliferation of different liver cancer cell lines both in vitro and in vivo, and therefore may serve as an important candidate drug for prevention and treatment of hepatocellular carcinoma." | 7.74 | [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells]. ( Lin, QH; Liu, SC; Tang, BD; Zhou, Q, 2007) |
| "Both low COX-2 expressing PLC/PRF/5 and high COX-2 expressing HuH7 cells, and nude mice bearing hepatocellular carcinoma xenografts were used to study the effect and mechanisms of celecoxib on hepatocellular carcinoma cell growth." | 7.73 | In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. ( Cui, W; Hu, KQ; Yu, CH, 2005) |
| "Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis." | 6.84 | Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. ( Chen, S; Huang, ZY; Tang, CW; Tong, H; Wei, B; Xie, YM; Zhang, LH; Zhang, MG, 2017) |
| "MATERIAL AND METHODS We treated hepatocellular carcinoma (HCC) Huh-7 cells and tumor xenograft mice models with celecoxib to test its effects on the tumor." | 5.51 | Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1. ( Dai, H; Ma, R; Pan, L; Zhang, S, 2019) |
| "The vast majority of hepatocellular carcinomas (HCC), however, are resistant to TRAIL." | 5.36 | Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. ( Hao, C; Ji, B; Liu, Y; Lu, G; Wang, G; Wei, F, 2010) |
| "Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma." | 3.91 | Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. ( Chen, L; Deng, X; Hu, J; Li, X; Qiu, Z; Sheng, L; Zhang, C; Zheng, G; Zhou, J, 2019) |
| "Epirubicin is a chemotherapy agent for hepatocellular carcinoma (HCC)." | 3.88 | Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats. ( Chan, HH; Chang, YC; Chen, YA; Chu, TH; Hu, TH; Huang, SC; Ma, YL; Tai, MH; Wang, EM; Wen, ZH; Weng, WT; Wu, DC; Wu, JC, 2018) |
| "Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several types of cancer, including hepatocellular carcinoma (HCC)." | 3.80 | Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. ( Chan, HH; Cheng, KH; Chu, TH; Hsu, PI; Hu, TH; Kung, ML; Kuo, HM; Lai, KH; Lin, SW; Liu, LF; Ma, YL; Sun, CK; Tai, MH; Wang, EM; Wen, ZH, 2014) |
| "Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed." | 3.79 | Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. ( Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M, 2013) |
| "To validate the efficacy of an innovative multimodality therapy with transcatheter arterial embolization (TAE) plus octreotide and celecoxib in reducing neoangiogenesis and prolonging the survival of rabbits with hepatocellular carcinoma." | 3.79 | Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. ( Fu, P; Gao, JH; Huang, ZY; Li, X; Tang, CW; Tong, H; Wen, FQ; Wen, SL; Zhang, CL, 2013) |
| "To evaluate effects of celecoxib (a selective cox-2 inhibitor)combined with fluvastatin (a HMG-CoA reductase inhibitor) on tumor growth and cell apoptosis in hepatocellular carcinoma xenograft in nude mice." | 3.76 | [Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellular carcinoma]. ( Gao, J; Ge, YS; Jia, WD; Li, JS; Ma, JL; Xu, GL; Yu, JH, 2010) |
| " We have reported that apoptosis can be restored in human multidrug-resistant (MDR) hepatocellular carcinoma cell lines by celecoxib." | 3.75 | Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. ( Bottini, C; Fantappiè, O; Mazzanti, R; Platini, F; Solazzo, M; Tessitore, L, 2009) |
| "We previously reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, suppresses growth of human hepatocellular carcinoma (HCC) cells through both COX-2 dependence and independence." | 3.74 | In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. ( Cui, W; Hu, KQ; Hu, SX; Tang, ZY, 2008) |
| "Celecoxib can inhibit the proliferation of different liver cancer cell lines both in vitro and in vivo, and therefore may serve as an important candidate drug for prevention and treatment of hepatocellular carcinoma." | 3.74 | [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells]. ( Lin, QH; Liu, SC; Tang, BD; Zhou, Q, 2007) |
| "Both low COX-2 expressing PLC/PRF/5 and high COX-2 expressing HuH7 cells, and nude mice bearing hepatocellular carcinoma xenografts were used to study the effect and mechanisms of celecoxib on hepatocellular carcinoma cell growth." | 3.73 | In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. ( Cui, W; Hu, KQ; Yu, CH, 2005) |
| "Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis." | 2.84 | Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. ( Chen, S; Huang, ZY; Tang, CW; Tong, H; Wei, B; Xie, YM; Zhang, LH; Zhang, MG, 2017) |
| "MATERIAL AND METHODS We treated hepatocellular carcinoma (HCC) Huh-7 cells and tumor xenograft mice models with celecoxib to test its effects on the tumor." | 1.51 | Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1. ( Dai, H; Ma, R; Pan, L; Zhang, S, 2019) |
| "When HepG2 hepatoma cells were treated with celecoxib, the expression of the genes in de novo sphingolipid biosynthesis and sphingomyelinase pathway was upregulated and cellular ceramide was elevated." | 1.46 | Celecoxib-mediated activation of endoplasmic reticulum stress induces de novo ceramide biosynthesis and apoptosis in hepatoma HepG2 cells mobilization. ( Kim, GT; Kim, JY; Lee, K; Maeng, HJ; Park, TS; Song, JH; Song, YJ, 2017) |
| "Treatment with celecoxib and IFN-α synergistically inhibited cell proliferation in a dose- and time-dependent manner." | 1.42 | Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma. ( Burns, M; Dan, H; Li, Q; Liu, C; Liu, J; Liu, N; Qiu, X; Wang, X; Wu, Q; Xia, M; Xie, H; Yang, D; Zhu, H; Zuo, C, 2015) |
| "Celecoxib is a potent nonsteroidal anti-inflammatory drug that has demonstrated promise in cancer chemoprevention and treatment." | 1.40 | Celecoxib induces apoptosis via a mitochondria‑dependent pathway in the H22 mouse hepatoma cell line. ( Chen, L; Kan, M; Li, J; Pan, Y; Qiao, P; Shao, D; Wang, Z; Xiao, X, 2014) |
| "Celecoxib has been shown to have antitumor effect in previous studies but the mechanisms are unclear." | 1.40 | Celecoxib-induced increase in cytosolic Ca(2+) levels and apoptosis in HA59T human hepatoma cells. ( Cheng, HH; Cheng, JS; Chi, CC; Chou, CT; Jan, CR; Kuo, CC; Liang, WZ; Liu, SI; Lu, T; Lu, YC; Tseng, LL, 2014) |
| "Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells." | 1.39 | Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. ( Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G, 2013) |
| "Human hepatoma cell lines were treated with lipopolysaccharide (LPS) or cyclooxygenase-2 inhibitor, Celecoxib, and in vitro proliferation, apoptosis, and cell cycle progression were assessed." | 1.39 | Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways. ( Bai, L; Mao, ZY; Su, D; Wang, LJ; Zhang, T, 2013) |
| "Celecoxib treatment resulted in significantly altered expression levels of 240 and 403 transcripts in Huh7 and HepG2 cells, respectively." | 1.37 | COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. ( Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Giannitrapani, L; Lampiasi, N; McCubrey, JA; Montalto, G; Sardina, F, 2011) |
| "A new non-cytotoxic therapy that SOM230 (pasireotide)，a somatostatin analogue (SSTA) combined with celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor was tested in nude mice bearing HepG2 xenografts." | 1.37 | SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts. ( Chen, S; Tang, CW; Wang, CH; Xie, Y, 2011) |
| "The vast majority of hepatocellular carcinomas (HCC), however, are resistant to TRAIL." | 1.36 | Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. ( Hao, C; Ji, B; Liu, Y; Lu, G; Wang, G; Wei, F, 2010) |
| "Celecoxib was found to inhibit the proliferation of H22 cells in a dose- and time-dependent manner." | 1.36 | The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway. ( Chen, L; Lv, X; Xiang, D; Xu, Z; Zhang, M; Zhang, X, 2010) |
| "Inhibition of hepatoma cells by cyclooxygenase (COX)-2-dependent and -independent mechanisms has been shown previously." | 1.34 | R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. ( Behari, J; Leoni, L; Micsenyi, A; Monga, SP; Muller, P; Otruba, W; Sekhon, SS; Thompson, MD; Zeng, G, 2007) |
| "Celecoxib can inhibit proliferation and induce apoptosis of hepatoma cell strains in a dose- and time-dependent manner." | 1.33 | Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis. ( Leng, J; Liu, NB; Pan, C; Peng, T; Shen, B; Yao, YY, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (34.88) | 29.6817 |
| 2010's | 26 (60.47) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, B | 1 |
| Chen, Z | 1 |
| Zhang, X | 2 |
| Wang, Z | 4 |
| Yao, Y | 1 |
| Wu, X | 1 |
| Qiu, J | 1 |
| Lin, H | 1 |
| Yu, L | 1 |
| Tu, H | 1 |
| Tang, N | 1 |
| Dai, H | 1 |
| Zhang, S | 1 |
| Ma, R | 1 |
| Pan, L | 1 |
| Lee, SH | 1 |
| Moon, HJ | 1 |
| Lee, YS | 1 |
| Kang, CD | 1 |
| Kim, SH | 1 |
| Tong, H | 3 |
| Wei, B | 2 |
| Chen, S | 2 |
| Xie, YM | 1 |
| Zhang, MG | 1 |
| Zhang, LH | 1 |
| Huang, ZY | 2 |
| Tang, CW | 3 |
| Chu, TH | 2 |
| Chan, HH | 2 |
| Hu, TH | 2 |
| Wang, EM | 2 |
| Ma, YL | 2 |
| Huang, SC | 1 |
| Wu, JC | 1 |
| Chang, YC | 1 |
| Weng, WT | 1 |
| Wen, ZH | 2 |
| Wu, DC | 1 |
| Chen, YA | 1 |
| Tai, MH | 2 |
| Qiu, Z | 1 |
| Zhang, C | 1 |
| Zhou, J | 1 |
| Hu, J | 1 |
| Sheng, L | 1 |
| Li, X | 4 |
| Chen, L | 3 |
| Deng, X | 1 |
| Zheng, G | 1 |
| Jiménez-Luévano, MÁ | 1 |
| Rodríguez-Chávez, JL | 1 |
| Ramírez-Flores, S | 1 |
| Rodríguez-Villa, P | 1 |
| Jiménez-Partida, MÁ | 1 |
| Cervantes-Rodríguez, G | 1 |
| Hernández-Flores, G | 1 |
| Solís-Martínez, R | 1 |
| Bravo-Cuellar, A | 1 |
| Morisaki, T | 1 |
| Umebayashi, M | 1 |
| Kiyota, A | 1 |
| Koya, N | 1 |
| Tanaka, H | 1 |
| Onishi, H | 1 |
| Katano, M | 1 |
| Wang, LJ | 1 |
| Bai, L | 1 |
| Su, D | 1 |
| Zhang, T | 1 |
| Mao, ZY | 1 |
| Cervello, M | 3 |
| Bachvarov, D | 2 |
| Lampiasi, N | 3 |
| Cusimano, A | 2 |
| Azzolina, A | 3 |
| McCubrey, JA | 3 |
| Montalto, G | 3 |
| Sui, W | 1 |
| Zhang, Y | 1 |
| Jia, Q | 1 |
| Wu, L | 1 |
| Zhang, W | 1 |
| Kuo, HM | 1 |
| Liu, LF | 1 |
| Sun, CK | 1 |
| Kung, ML | 1 |
| Lin, SW | 1 |
| Cheng, KH | 1 |
| Lai, KH | 1 |
| Hsu, PI | 1 |
| Cheng, HH | 1 |
| Chou, CT | 1 |
| Lu, YC | 1 |
| Lu, T | 1 |
| Chi, CC | 1 |
| Tseng, LL | 1 |
| Liu, SI | 1 |
| Cheng, JS | 1 |
| Kuo, CC | 1 |
| Liang, WZ | 1 |
| Jan, CR | 1 |
| Shao, D | 1 |
| Kan, M | 1 |
| Qiao, P | 1 |
| Pan, Y | 2 |
| Xiao, X | 1 |
| Li, J | 1 |
| Fantappiè, O | 3 |
| Sassoli, C | 1 |
| Tani, A | 1 |
| Nosi, D | 1 |
| Marchetti, S | 1 |
| Formigli, L | 1 |
| Mazzanti, R | 3 |
| Zuo, C | 1 |
| Qiu, X | 1 |
| Liu, N | 1 |
| Yang, D | 1 |
| Xia, M | 1 |
| Liu, J | 2 |
| Wang, X | 1 |
| Zhu, H | 1 |
| Xie, H | 2 |
| Dan, H | 1 |
| Li, Q | 1 |
| Wu, Q | 1 |
| Burns, M | 1 |
| Liu, C | 1 |
| Tang, C | 1 |
| Maeng, HJ | 1 |
| Song, JH | 1 |
| Kim, GT | 1 |
| Song, YJ | 1 |
| Lee, K | 1 |
| Kim, JY | 1 |
| Park, TS | 1 |
| Gao, L | 1 |
| Chai, N | 1 |
| Song, J | 1 |
| Wang, J | 1 |
| Song, Z | 1 |
| Chen, C | 1 |
| Zhao, L | 1 |
| Sun, S | 1 |
| Wu, K | 1 |
| Feitelson, MA | 1 |
| Fan, D | 1 |
| Cui, W | 2 |
| Hu, SX | 1 |
| Tang, ZY | 1 |
| Hu, KQ | 2 |
| Platini, F | 2 |
| Bottini, C | 1 |
| Solazzo, M | 2 |
| Tessitore, L | 2 |
| Roy, KR | 1 |
| Reddy, GV | 1 |
| Maitreyi, L | 1 |
| Agarwal, S | 1 |
| Achari, C | 1 |
| Vali, S | 1 |
| Reddanna, P | 1 |
| Lu, G | 1 |
| Liu, Y | 2 |
| Ji, B | 1 |
| Wei, F | 1 |
| Hao, C | 1 |
| Wang, G | 1 |
| Xu, Z | 1 |
| Zhang, M | 1 |
| Lv, X | 1 |
| Xiang, D | 1 |
| Gao, J | 1 |
| Li, JS | 1 |
| Xu, GL | 1 |
| Jia, WD | 1 |
| Ma, JL | 1 |
| Yu, JH | 1 |
| Ge, YS | 1 |
| Sardina, F | 1 |
| Giannitrapani, L | 1 |
| Yin, J | 1 |
| Liu, B | 1 |
| Li, B | 1 |
| Liu, Z | 1 |
| Xie, X | 1 |
| Lv, Z | 1 |
| Gao, S | 1 |
| Guang, J | 1 |
| Liu, A | 1 |
| Li, H | 1 |
| Li, C | 1 |
| Lin, J | 1 |
| Xie, Y | 1 |
| Wang, CH | 1 |
| Umezawa, K | 1 |
| Zhang, CL | 1 |
| Gao, JH | 1 |
| Wen, SL | 1 |
| Wen, FQ | 1 |
| Fu, P | 1 |
| Kern, MA | 2 |
| Schubert, D | 1 |
| Sahi, D | 1 |
| Schöneweiss, MM | 1 |
| Moll, I | 1 |
| Haugg, AM | 2 |
| Dienes, HP | 1 |
| Breuhahn, K | 2 |
| Schirmacher, P | 2 |
| Leng, J | 2 |
| Han, C | 1 |
| Demetris, AJ | 1 |
| Michalopoulos, GK | 1 |
| Wu, T | 1 |
| Graepler, F | 1 |
| Gregor, M | 1 |
| Lauer, UM | 1 |
| Malka, D | 1 |
| Pacault, V | 1 |
| De Baere, T | 1 |
| Ducreux, M | 1 |
| Boige, V | 1 |
| Yu, CH | 1 |
| Liu, NB | 1 |
| Peng, T | 1 |
| Pan, C | 1 |
| Yao, YY | 1 |
| Shen, B | 1 |
| Zuo, CH | 1 |
| Li, ZR | 1 |
| Zhou, X | 1 |
| Ouyang, YZ | 1 |
| Zhou, ZY | 1 |
| Zeng, L | 1 |
| Koch, AF | 1 |
| Schilling, T | 1 |
| Walczak, H | 1 |
| Fleischer, B | 1 |
| Trautwein, C | 1 |
| Michalski, C | 1 |
| Schulze-Bergkamen, H | 1 |
| Friess, H | 1 |
| Stremmel, W | 1 |
| Krammer, PH | 1 |
| Müller, M | 1 |
| Song, HJ | 1 |
| Kim, YS | 2 |
| Han, CH | 1 |
| Jang, JY | 1 |
| Kim, JH | 1 |
| Cheon, YK | 1 |
| Moon, JH | 1 |
| Cho, YD | 1 |
| Shim, CS | 1 |
| Kwon, KH | 1 |
| Kim, BS | 1 |
| Behari, J | 1 |
| Zeng, G | 1 |
| Otruba, W | 1 |
| Thompson, MD | 1 |
| Muller, P | 1 |
| Micsenyi, A | 1 |
| Sekhon, SS | 1 |
| Leoni, L | 1 |
| Monga, SP | 1 |
| Lasagna, N | 1 |
| Tang, BD | 1 |
| Zhou, Q | 1 |
| Lin, QH | 1 |
| Liu, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Celebrex and Metformin for Postoperative Hepatocellular Carcinoma[NCT03184493] | Phase 3 | 200 participants (Anticipated) | Interventional | 2017-06-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
[Anti-angiogenic therapy for gastrointestinal tumours].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2005 |
1 trial available for celecoxib and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2017 |
41 other studies available for celecoxib and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Celecoxib; Dinoprostone; Gastroin | 2023 |
Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Prol | 2019 |
Potentiation of TRAIL‑induced cell death by nonsteroidal anti‑inflammatory drug in human hepatocellular carcinoma cells through the ER stress‑dependent autophagy pathway.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2020 |
Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Celecoxib; C | 2018 |
Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cycloo | 2019 |
Treatment of hepatocarcinoma with celecoxib and pentoxifylline: a case report
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ce | 2018 |
Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellu | 2013 |
Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; Disease Progres | 2013 |
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Prolifera | 2013 |
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell | 2014 |
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cyc | 2014 |
Celecoxib-induced increase in cytosolic Ca(2+) levels and apoptosis in HA59T human hepatoma cells.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; C | 2014 |
Celecoxib induces apoptosis via a mitochondria‑dependent pathway in the H22 mouse hepatoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; Ca | 2014 |
Mitochondria of a human multidrug-resistant hepatocellular carcinoma cell line constitutively express inducible nitric oxide synthase in the inner membrane.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carcinoma, Hepatocellula | 2015 |
Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspases; Celecoxib; Cell Line | 2015 |
Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Celecoxib; Chemoembolizat | 2015 |
Celecoxib-mediated activation of endoplasmic reticulum stress induces de novo ceramide biosynthesis and apoptosis in hepatoma HepG2 cells mobilization.
Topics: Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Survival; Ceramides; Endopla | 2017 |
Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Caspase Inhibitors; Caspases; Celecoxib; Ce | 2009 |
In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice.
Topics: Acetylation; alpha-Fetoproteins; Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cy | 2008 |
Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Celec | 2009 |
Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocel | 2010 |
Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Campto | 2010 |
The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway.
Topics: Animals; Arachidonic Acid; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Hepatocellular | 2010 |
[Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellular carcinoma].
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibit | 2010 |
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Survival; Cycloo | 2011 |
The cyclooxygenase-2 inhibitor celecoxib attenuates hepatocellular carcinoma growth and c-Met expression in an orthotopic mouse model.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cycl | 2011 |
Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cyclooxyge | 2011 |
SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Celec | 2011 |
The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Hepatocellular; Celecoxib; | 2012 |
Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts.
Topics: Abdominal Neoplasms; Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Carcinoma, Hepatocellular; Carr | 2002 |
Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Division; Cyclooxygenas | 2003 |
Antitumoral effect of celecoxib in hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Celecoxib; Cyclooxygenase Inhibitors; Humans; Liver Neoplasms; Male | 2005 |
In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Prolife | 2005 |
Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Caspases; Celecoxib; Cell Line, Tumor; C | 2005 |
[Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice].
Topics: Angiopoietin-2; Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; C | 2006 |
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase | 2006 |
[A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Celeco | 2006 |
R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, | 2007 |
P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Prot | 2007 |
[Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells].
Topics: Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase | 2007 |